


## EARLY MTX STEP-UP PLAN FOR ACTIVE PERSISTENT OLIGIARTICULAR JIA



JADAS= Juvenile Arthritis Disease Activity Scale

---

Footnote 1: Adalimumab, etanercept (if no uveitis or IBD), golimumab, or infliximab (in line with the Norwegian LIS TNF BIO recommendations).

Footnote 2: If tried 2 anti TNFs, change mechanism to tocilizumab or abatacept.

The treatment plan is based on consensus treatment plans, expert reviews, and the American College of Rheumatology (ACR) treatment plans.

## References

1. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. *Arthritis Care Res (Hoboken)*. 2011 Apr;63(4):465-82
2. Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment. Calasan MB<sup>1</sup>, Wulffraat NM. *Expert Rev Clin Immunol*. 2014 Jul;10(7):843-54. doi: 10.1586/1744666X.2014.916617.
3. Consolaro Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. *Arthritis Rheum* 2009 May 15;61(5):658-66.